For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 7,987 | 6,225* | 6,437 | 5,822 |
| General and administrative | 2,495 | 2,612* | 2,596 | 2,185 |
| Total operating expenses | - | 8,836 | - | - |
| Operating loss | -10,482 | -8,836* | -9,033 | -8,007 |
| Other income, net | 447 | 560 | - | - |
| Total other income, net | - | 560* | 419 | 314 |
| Loss before income tax expense | -10,035 | -8,277* | -8,614 | -7,693 |
| Income tax expense | 7 | 10* | 6 | 6 |
| Net loss | -10,042 | -8,287* | -8,620 | -7,699 |
| Unrealized loss on marketable securities | -76 | -40* | 64 | -19 |
| Comprehensive loss | -10,118 | -8,328 | -8,556 | -7,718 |
| Basic EPS | -0.19 | -0.172 | -0.17 | -0.18 |
| Basic Average Shares | 53,793,490 | 48,354,593 | 49,630,119 | 42,957,619 |
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)